PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026Juntendo Medical Journal0 citationsOpen Access

Longitudinal Assessment of Metabolic Syndrome and Direct-Acting Antiviral (DAA) Treatment Adherence in Hepatitis C Patients

CMCHRISTA MATHEWSGSAUD GULMMMANAHIL MONIS

Key Points

  • This research aims to explore how metabolic syndrome affects adherence to DAA treatment in chronic hepatitis C patients over six months.
  • Longitudinal assessment of hepatitis C patients over six months.
  • Evaluation of metabolic syndrome risk factors.
  • Measurement of adherence rates to DAA therapy throughout the study period.
  • Patients with metabolic syndrome showed lower adherence rates to DAA therapy.
  • Compliance varied significantly based on the severity of metabolic abnormalities.
  • The study identifies a clear linkage between metabolic syndrome and treatment adherence.

Abstract

Objectives Chronic hepatitis C is commonly associated with metabolic abnormalities that can influence adherence to direct-acting antiviral (DAA) therapy. This paper discussed the relationship between metabolic syndrome risk and compliance with DAA for 6 months.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

MATHEW et al. (2026) studied this question.

synapsesocial.com/papers/69b64c33b42794e3e660da5bhttps://doi.org/10.14789/ejmj.jmj25-0063-oa
Ask AI
Helpful
Bookmark
Share
View Full Paper